Abstract

IntroductionIndividuals with mental disorders, on average, die prematurely and may experience accelerated biological ageing.ObjectivesWe examined sex-specific associations between age and physiological measures in individuals with lifetime depression and healthy controls.MethodsUK Biobank recruited >500,000 participants, aged 37-73, between 2006–2010. Generalised additive models (GAMs) were used to examine associations between age and multiple cardiovascular, body composition, grip strength and lung function measures. Analyses were conducted separately in males and females with lifetime depression compared to healthy controls.ResultsAnalytical samples included up to 342,393 adults (mean age = 55.87 years, SD = 8.09; 52.61% females). We found statistically significant differences between individuals with lifetime depression and healthy controls for most physiological measures, with standardised mean differences between -0.145 and 0.156. There was some evidence that age-related changes in body composition, cardiovascular measures, lung function and heel bone mineral density followed different trajectories in individuals with lifetime depression. However, these differences did not uniformly narrow or widen with age. For example, BMI in females with lifetime depression was approximately 1.1 kg/m2 higher at age 40 and this difference narrowed to about 0.4 kg/m2 at age 70. In males, systolic blood pressure was approximately 1 mmHg lower in individuals with lifetime depression at age 45 and this difference widened to about 2.5 mmHg at age 65.ConclusionsEvidence of differences in ageing trajectories between individuals with lifetime depression and healthy controls was not uniform across physiological measures and differed by sex.DisclosureJM receives studentship funding from the Biotechnology and Biological Sciences Research Council (BBSRC) and Eli Lilly and Company Limited. CML is a member of the Scientific Advisory Board of Myriad Neuroscience.

Highlights

  • Individuals with mental disorders, on average, die prematurely and may experience accelerated biological ageing

  • 52 patients (79%), presented a severe current depressive episode based on clinical judgment

  • We examined sex-specific associations between age and physiological measures in individuals with lifetime depression and healthy controls

Read more

Summary

Objectives

A cohort Temporary Authorization for Use (ATUc) allowed to collect for a 6-month period the first data in real life Methods: On 02/08/2019 the French National Agency for Medicines and Health Product Safety granted an early access program for Esketamine nasal spray framed by a specific protocol for patients without therapeutic alternatives. Treatment management and safety were spontaneously reported by psychiatrists. 52 patients (79%), presented a severe current depressive episode based on clinical judgment. Since the beginning of the current depressive episode, all patients (66) were prescribed ≥2 antidepressants (mean 4.2). Data reported by French psychiatrists are the first collected in this specific population and provide descriptive information on patient characteristics, burden of disease; Esketamine management and practical use at hospital level.

Introduction
Findings
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call